文献速递心脏核医学肿瘤 PET/CT

18F-FDG与18F-FAPI PET/CT分子表型分析:推进支架内再狭窄的风险分层

Molecular phenotyping with 18F-FDG and 18F-FAPI PET/CT: advancing risk stratification in in-stent restenosis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-01

这项前瞻性研究纳入31例支架内再狭窄(ISR)患者和84条血管,以未干预冠脉为对照,行18F-FDG与18F-FAPI PET/CT并随访。结果显示ISR血管双示踪剂摄取均高于对照,快速复发型ISR(R-ISR)摄取高于普通型ISR(O-ISR),且18F-FAPI诊断效能优于18F-FDG,基线PET摄取与后续心血管终点相关。

要点

  • 18F-FAPI与18F-FDG PET/CT可显示ISR的分子异质性。
  • R-ISR在患者和血管水平的双示踪剂TBRmax均高于O-ISR。
  • 18F-FAPI的TBRmax诊断R-ISR的AUC优于18F-FDG。

核心结论

  • 18F-FAPI与18F-FDG PET/CT可揭示ISR的分子异质性,其中18F-FAPI更能识别快速复发亚型,有助于推进风险分层。

研究设计与样本

  • 共纳入31例参与者、84条血管;ISR血管39条,对照血管45条;主要终点为心血管死亡、靶血管相关心肌梗死或靶血管相关血运重建的复合终点。

主要发现

  • ISR血管(n=39)的18F-FDG与18F-FAPI摄取均高于对照血管(n=45)。
  • 患者水平TBRmax:18F-FAPI在R-ISR为4.10±1.41、O-ISR为1.75±0.50;18F-FDG在R-ISR为1.18±0.32、O-ISR为0.86±0.19(均P≤0.01)。
  • 血管水平TBRmax:18F-FAPI在R-ISR为4.07±1.29、O-ISR为1.65±0.50;18F-FDG在R-ISR为1.16±0.31、O-ISR为0.90±0.28(均P≤0.01)。
  • 18F-FAPI的TBRmax诊断效能优于18F-FDG,AUC分别为0.97(0.92-1.00)与0.75(0.58-0.91),P=0.01。
  • R-ISR组31例中6例达到终点;基线PET摄取与后续结局相关:18F-FAPI SUVmax的HR为2.28(95%CI:1.25-5.09,P=0.02),18F-FDG SUVmax的HR为33.2(95%CI:4.93-509,P=0.002)。

关键数值与推荐

  • ISR按复发时间间隔分为快速复发ISR(R-ISR)与普通ISR(O-ISR)。
  • 以SUVmax和TBRmax评估示踪剂摄取并比较诊断效能。
  • 主要终点为心血管死亡、靶血管相关心肌梗死或靶血管相关血运重建的复合终点。

临床怎么用

  • 对ISR患者可考虑行18F-FAPI与18F-FDG PET/CT评估分子表型,18F-FAPI对识别快速复发亚型更具优势。
  • 基线PET摄取与后续心血管终点相关,可用于辅助风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the potential of 18F-FDG and 18F-FAPI PET/CT for characterizing the pathophysiological heterogeneity of in-stent stenosis (ISR) and to assess their ability to differentiate between its clinically subtypes. METHODS: This prospective study enrolled participants with ISR selected from a cohort registry between December 2024 to August 2025, which was categorized into rapid recurrent ISR (R-ISR) and ordinary ISR (O-ISR) based on recurrence time interval. For vessel-level analysis, coronary arteries without intervention served as control. All participants underwent both 18F-FDG and 18F-FAPI PET/CT to assess coronary uptake and evaluated the performance of maximum standardized uptake value (SUVmax) and maximum target-to-background ratio (TBRmax) in differentiating ISR from control vessels, as well as R-ISR from O-ISR. All patients were followed-up. The primary endpoint was a composite of cardiovascular death, target-vessel-related myocardial infarction, or target-vessel-related revascularization. Differences in the diagnostic performance of PET parameters and associations with outcomes were assessed. RESULTS: Thirty-one participants and 84 vessels were included. ISR vessels (n = 39) demonstrated higher uptake in 18F-FDG and 18F-FAPI than control (n = 45). R-ISR exhibited higher uptake compared to O-ISR on both patient-level (TBRmax: 18F-FAPI, 4.10 ± 1.41 vs. 1.75 ± 0.50; 18F-FDG, 1.18 ± 0.32 vs. 0.86 ± 0.19) and vessel-level (TBRmax: 18F-FAPI, 4.07 ± 1.29 vs. 1.65 ± 0.50; 18F-FDG, 1.16 ± 0.31 vs. 0.90 ± 0.28) (all P ≤ 0.01). 18F-FAPI showed better diagnostic efficacy compared to 18F-FDG (AUC of TBRmax: 0.97 [0.92-1.00] vs. 0.75 [0.58-0.91], P = 0.01]. Six of 31 participants within R-ISR group reached the endpoint. Baseline PET uptake was associated with subsequent outcome (18F-FAPI SUVmax, HR, 2.28 [95%CI: 1.25-5.09], P = 0.02; 18F-FDG SUVmax, HR, 33.2 [95%CI: 4.93-509], P = 0.002). CONCLUSION: 18F-FAPI and 18F-FDG PET/CT reveals the molecular heterogeneity of ISR, with 18F-FAPI better identifying the rapid-recurrence subtype for advancing risk stratification. TRIAL REGISTRATION: NCT05437965. Registered 24 June 2022.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jia L, Wang K, Lin Z, et al. Molecular phenotyping with 18F-FDG and 18F-FAPI PET/CT: advancing risk stratification in in-stent restenosis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42380497. doi:10.1007/s00259-026-08036-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。